Group 1 - Eikon Therapeutics raised $381.2 million in its IPO by issuing approximately 21.2 million shares at a price of $18 per share, which is at the upper end of its target range of $16 to $18 [1][2] - The IPO market in the U.S. is showing signs of recovery in 2026, following a slowdown due to a government shutdown in October last year that delayed many companies' listing plans [1] - Eikon Therapeutics was founded in 2019 by Nobel laureates and is currently developing multiple experimental cancer therapies, with its lead candidate EIK1001 undergoing mid-to-late stage clinical trials for skin cancer in collaboration with Merck's Keytruda [1] Group 2 - Eikon Therapeutics' stock will begin trading on Nasdaq under the ticker symbol "EIKN" [2] - The underwriters for the IPO include major financial institutions such as JPMorgan, Morgan Stanley, Bank of America Securities, Cantor, and Mizuho Securities [2]
生物医药公司Eikon Therapeutics(EIKN.US)IPO定价18美元募资3.8...